Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Mignot, Grégoire ^a,b   Hervieu, Alice ^a,b,c   Vabres, Pierre ^b,c   Dalac, Sophie ^c   Jeudy, Geraldine ^c   Bel, Blandine ^c   Apetoh, Lionel ^a,b,d   Ghiringhelli, François ^a,b,d  

^a Institut Médical de Génétique et d Immunologie   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c HÔPITAL DU BOCAGE   (France)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; ALKYLATING AGENT; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; COHORT ANALYSIS; CYTOTOXICITY TEST; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MELANOMA; MELANOMA CELL; MELANOMA METASTASIS; MIDDLE AGED; MONOCYTE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; OBSERVATIONAL STUDY; POLARIZATION; PROSPECTIVE STUDY; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VERY ELDERLY; BLOOD; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL SURVIVAL; DACARBAZINE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 84929203964     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105907     Document Type: Article

References (29)

1. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, et al. (2010) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29: 482-491.
2. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, et al. (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050-1059. (Pubitemid 47517504)
3. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, et al. (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15: 1170-1178.
4. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61. (Pubitemid 46067386)
5. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, et al. (2010) Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 120: 457-471.
6. Mignot G, Ullrich E, Bonmort M, Menard C, Apetoh L, et al. (2008) The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. J Immunol 180: 6477-6483.
7. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, et al. (2010) 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 70: 3052-3061.
8. Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, et al. (2013) Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 19: 57-64.
9. Hervieu A, Mignot G, Ghiringhelli F (2013) Dacarbazine mediate antimelanoma effects via NK cells. Oncoimmunology 2: e23714.
10. Hervieu A, Rebe C, Vegran F, Chalmin F, Bruchard M, et al. (2013) Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J Invest Dermatol 133: 499-508.
11. Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 23: 488-496.
12. Rosenberg SA (2011) Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol 8: 577-585.
13. Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ (2012) Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 13: e32-42.
14. Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, et al. (2003) Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science 302: 1041-1043. (Pubitemid 37386196)
15. Gordon SM, Chaix J, Rupp LJ, Wu J, Madera S, et al. (2012) The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 36: 55-67.
16. Duran-Aniotz C, Segal G, Salazar L, Pereda C, Falcon C, et al. (2013) The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses. Cancer Immunol Immunother 62: 761-772.
17. Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, et al. (2012) PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 35: 169-178.
18. von Euw E, Chodon T, Attar N, Jalil J, Koya RC, et al. (2009) CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 7: 35.
19. Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, et al. (2011) Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res 71: 661-665.
20. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, et al. (2008) Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373.
21. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, et al. (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31: 787-798.
22. Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, et al. (2013) Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol 190: 4899-4909.
23. Montes CL, Chapoval AI, Nelson J, Orhue V, Zhang X, et al. (2008) Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion. Cancer Res 68: 870-879. (Pubitemid 351206765)
24. De Panfilis G, Campanini N, Santini M, Mori G, Tognetti E, et al. (2008) Phase- and stage-related proportions of T cells bearing the transcription factor FOXP3 infiltrate primary melanoma. J Invest Dermatol 128: 676-684. (Pubitemid 351252653)
25. Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L (2008) NK cells at the interface between innate and adaptive immunity. Cell Death Differ 15: 226-233.
26. Poli A, Michel T, Thérésine M, Andrès E, Hentges F, et al. (2009) CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 126: 458-465.
27. Messaoudene M, Fregni G, Fourmentraux-Neves E, Chanal J, Maubec E, et al. (2014) Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. Cancer Res 74: 81-92.
28. Fregni G, Perier A, Pittari G, Jacobelli S, Sastre X, et al. (2011) Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy. Clin Cancer Res 17: 2628-2637.
29. Fregni G, Messaoudene M, Fourmentraux-Neves E, Mazouz-Dorval S, Chanal J, et al. (2013) Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages. PLoS One 8: e76928.